May 16, 2024

Office of the Attorney General
State of Vermont

via email to: AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A.§4637(c), Biogen is hereby providing additional information related to the 3-day notice of the introduction of a new prescription drug in the commercial market as submitted on May 3, 2024:

NDC	Description	Date Commercially Available	Wholesale Acquisition Cost (WAC)*
64406-0022-01	TOFIDENCE 200 mg/10 mL (20 mg/mL) in a single-dose vial	05/01/2024	$1,110.00
64406-0023-01	TOFIDENCE 400 mg/20 mL (20 mg/mL) in a single-dose vial	05/01/2024	$2,220.00
64406-0024-01	TOFIDENCE 80 mg/4 mL (20 mg/mL) in a single-dose vial	05/01/2024	$444.00

**Price to wholesalers, without regard to prompt pay or other discounts, rebates, chargebacks, or any fees paid to wholesalers for services performed. Does not represent prices charged to other customers or classes of trade.*

Additional information:

Requested Information	Biogen Submission
A description of the marketing and pricing plans used in the launch of the new drug in the United States and Internationally	TOFIDENCE will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences. Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients, 2. Present and Future Benefit to Society, 3. Fulfilling our commitment to Innovation, 4. Evolution toward Value Based Care, and 5. Affordability & Sustainability. Further information can be found at: https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf

Requested Information	Biogen Submission
The estimated volume of patients who may be prescribed the drug	1,550,000 The estimated number of patients provided is the current number of people in the United States who are estimated to be suffering from rheumatoid arthritis.
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	TOFIDENCE was not granted breakthrough therapy designation or priority review
The date and price of acquisition if the drug was not developed by the manufacturer	N/A

Please let me know if you need any additional information.

Best Regards,

Sooah Cheung
Associate Director, Contracts & Pricing Governance
Biogen | 225 Binney Street | Cambridge, MA | 02142
Email: sooah.cheung@biogen.com | Direct: 781-464-1606